Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCheng-En Hsieh
About this trial
To prospectively investigate and integrate radiomic and immunologic signatures in patients with nasopharyngeal carcinoma (NPC) treated with either proton or photon radiotherapy, with the aim of identifying biomarkers associated with treatment response, toxicity, and long-term outcomes.
Eligibility criteria
Qualifiers
Willingness to provide written informed consent.
Pathologically confirmed diagnosis of nasopharyngeal carcinoma
Age ≥18 years
ECOG performance status 0-1
Disqualifiers
Presence of distant metastasis
Patients with AJCC v.9 cT1N0M0 disease who undergo radiotherapy alone.
Synchronous or prior invasive malignancy, unless disease-free for at least 2 years.
Prior radiotherapy to the head and neck region
Trial design
Treatments tested in this trial
- Proton chemoradiotherapy
- Photon chemoradiotherapy
Treatment groups
500 Participants
are divided into 2 treatment groupsSponsors and collaborators
Cheng-En Hsieh
Lead sponsor
Chang Gung Memorial Hospital
Sponsor institution
Source ClinicalTrials.gov